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Pfizer South Africa announced on 13 April 2005 that the
company would suspend the sale of the oral Cox-2 inhibitor
Bextra with immediate effect. The suspension is voluntary and
at the request of the Medicines Control Council.
This suspension of sales does not stem from any new
scientific information, but is a direct result of the request by the
Council. While Pfizer respectfully disagrees with the Council
decision and believes that Bextra is a valuable treatment
alternative for the relief of short-term postoperative pain and
primary dysmenorrhoea, the company will comply with the
request pending investigation of the entire NSAID and Cox-2
class of medicines. 
The Medicines Control Council request for a voluntary
suspension follows a similar request from the US Food and
Drug Administration and various other regulatory bodies,
including the European Medicines Agency, EMEA. In coming to
their decision, the FDA considered that unproven
cardiovascular safety in long-term use, coupled with the
possibility of severe skin reactions, led to an unfavourable risk-
benefit profile. Bextra, which was launched in South Africa in
August 2004, is only indicated for the treatment of acute, mild
to moderate postoperative pain and primary dysmenorrhoea
and not for long-term use in rheumatoid or osteoarthritis, as in
the USA. Treatment typically runs for 5 days. 
To this end, the following advice is offered: 
Prescribers are advised not to initiate treatment in new
patients and physicians should consider whether patients
currently on Bextra should finish their current course of
treatment while being monitored or be switched immediately to
alternative therapeutic options. 
Pharmacists are advised not to dispense further prescriptions
for Bextra and to advise patients receiving Bextra to return to
their doctors to discuss alternative therapeutic options. In
addition, pharmacists are advised that stock will be withdrawn
from their sites, through a withdrawal notification procedure. 
Patients are advised to make an appointment with their
health care providers to discuss their current treatment with
Bextra and alternative treatment options. 
For further drug-related information, please call Pfizer on 
086 073 4937.
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or hospital visits and antenatal consultations. Awareness
should be raised by means of pamphlets and posters
explaining the dangers of smoking in pregnancy, using
layman’s terms and illustrations. These could be made freely
available in waiting areas and consultation rooms.
On a personal level, the patient should be addressed in a
non-judgemental manner, taking into account her psychosocial
situation, e.g. social pressures, and the presence of spouse,
partner or family members who smoke. The aim should be to
enlighten the patient and her family and friends regarding the
importance of smoking cessation in pregnancy. 
An effective way to persuade smokers to quit in pregnancy
during a 5  - 15-minute consultation (Table II) has recently been
suggested.5
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Table II. Smoking cessation intervention for pregnant
patients
Consultation scheme
1. Ask Enquiring about smoking status
2. Advise Provide strong advice to quit, with 
personalised messages on benefits of 
quitting and the impact of smoking 
on the woman and fetus 
3. Assess Assess the willingness of the patient to quit 
within the next 30 days
4. Assist Suggest and encourage problem-solving 
methods
Provide social support
Arrange social support
Provide pregnancy-specific, self-help 
smoking cessation materials
5. Arrange Assess status in follow-up visits, 
encourage cessation if still smoking
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